Rivaroxaban - Bayer/Johnson & Johnson Pharmaceutical Research & Development
Alternative Names: BAY-59-7939; JNJ-39039039; XareltoLatest Information Update: 26 Dec 2023
At a glance
- Originator Bayer; Johnson & Johnson Pharmaceutical Research & Development
- Developer Bayer; Janssen Research & Development; Johnson & Johnson; Population Health Research Institute
- Class Amides; Anticoagulants; Antithrombotics; Cardiovascular therapies; Chlorinated hydrocarbons; Ketones; Morpholines; Oxazolidinones; Small molecules; Thiophenes
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Thromboembolism; Thrombosis; Venous thromboembolism
- Registered Acute coronary syndromes; Cardiovascular disorders
- Phase III Arterial thrombosis; Peripheral arterial disorders; Venous thrombosis
- Phase II Coronary thrombosis
- No development reported Heart failure
Most Recent Events
- 11 Nov 2023 Adverse events and efficacy data from the phase III VOYAGER PAD trial in Peripheral arterial disorders presented at the American Heart Association Scientific Sessions (AHA-2023)
- 11 Nov 2023 Efficacy data from the phase III VOYAGER PAD trial for Peripheral arterial disorders presented at American Heart Association Scientific Sessions 2023 (AHA-2023)
- 18 May 2023 Janssen Research & Development terminates phase III trial in(PREVENT-HD) in Venous thrombosis and Arterial thrombosis in USA (PO)